Relay Therapeutics, Inc. (RLAY) has been beaten down lately with too much selling pressure. While the stock has lost 24% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscill ...

Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D Plan to initiate 2L pivotal trial of RLY-2608 + fulvestrant in 2025 Approximately $840 million in cash, cash equivalents and investments at end of Q3 2024, expected to fund operations into second half of 2027 CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company trans ...

CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, November 6, 2024. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming ...

Relay Therapeutics, Inc. (RLAY) shares soared 6.7% in the last trading session to close at $8.11. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 17.8% gain over the past four weeks. The sudden surge in the stock price can be attributed to a positive investor mindset regarding the company's pipeline progress. Relay Therapeutics is leveraging its Dynamo platform to initially focus on precision oncology. The company has several can ...

Monday, Relay Therapeutics Inc. RLAY shared interim data for RLY-2608 from the ReDiscover study of RLY-2608 alone, in combination with fulvestrant, and in combination with fulvestrant and ribociclib or atirmociclib (Pfizer Inc's PFE selective CDK4 inhibitor). The clinical benefit rate (CBR) was 57% in heavily pretreated patients. RLY-2608 is a pan-mutant and isoformselective inhibitor of PI3Kα. Oppenheimer downgraded Relay Therapeutics, noting the upcoming data from competitors. "We believe that approved PI ...

CAMBRIDGE, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today that it has commenced an underwritten public offering of $200 million of shares of its common stock. Relay Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of c ...

U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining around 1% on Monday. The Dow traded up 1.08% to 40,781.71 while the NASDAQ rose 0.76% to 16,818.23. The S&P 500 also rose, gaining, 0.95% to 5,459.48. Check This Out: Top 3 Financials Stocks That Could Blast Off In September Leading and Lagging Sectors Consumer discretionary shares surged by 1.8% on Monday. In trading on Monday, communication services shares rose by just 0.1%. Top Headline U.S. wholesale inventories increased by 0 ...

Monday, Relay Therapeutics Inc. RLAY shared interim data for RLY-2608 from ReDiscover study, an ongoing first-in-human study, to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of RLY-2608 alone, in combination with fulvestrant, and combination with fulvestrant and ribociclib or atirmociclib (Pfizer Inc's PFE selective CDK4 inhibitor). The data showed that despite heavy pre-treatment, patients with PI3Kα-mutated, HR+, HER2- locally advanced or metasta ...

Announced 3 new programs, including genetic disease programs in vascular malformations, Fabry disease, as well as precision oncology program with NRAS-specific inhibitor Initiated global clinical trial collaboration with Pfizer for combination development of RLY-2608 + fulvestrant + atirmociclib (CDK4i) in PI3Kα-mutated HR+/HER2- metastatic breast cancer, with clinical start planned by end of 2024 Approximately $688 million in cash, cash equivalents and investments at end of Q2 2024, expected to fund operat ...

CAMBRIDGE, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report second quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Tuesday, August 6, 2024. About Relay Therapeutics Contact: Megan Goulart 617-545-5526 mgoulart@relaytx.com Media: Dan Budwick 1AB 973-271-6085 dan@1 ...